UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $54.37 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,537,324 shares of the company’s stock after purchasing an additional 196,261 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.31% of Teva Pharmaceutical Industries worth $54,369,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter worth $39,000. New Age Alpha Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $43,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $54,000. Banque Cantonale Vaudoise bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $74,000. Finally, Brooklyn Investment Group increased its position in shares of Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company’s stock worth $77,000 after acquiring an additional 4,014 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. This trade represents a 47.19% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $19.96 on Monday. The firm has a 50-day moving average of $17.31 and a 200-day moving average of $16.50. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The stock has a market cap of $22.89 billion, a PE ratio of -124.75, a P/E/G ratio of 1.16 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to analysts’ expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries’s quarterly revenue was up .3% compared to the same quarter last year. During the same quarter last year, the company posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, June 26th. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a “buy” rating and a $24.00 price objective for the company. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of “Buy” and a consensus price target of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.